CIK 0001656634
GRTS Gritstone bio, Inc.
Insider trading from SEC Form 4. Last filing Apr 8, 2025.
Gritstone bio, Inc. (GRTS) has 9 SEC Form 4 filings on file from 8 insiders, the latest filed on Apr 8, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at GRTS. The newest: Vassiliki Economides (EVP, CHIEF FINANCIAL OFFICER) sold $180 of stock on Dec 18, 2024, filed Dec 20, 2024, scored 22 (weak).
1 Form 144 notice of planned sales is on file, the latest filed Dec 18, 2024.
Last 90 days
Signals
Open-market buys and sells at Gritstone bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Vassiliki Economides EVP, CHIEF FINANCIAL OFFICER sell | $180 12,000 shares | -5% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 18, 2024 | Economides Vassiliki Officer | 12,000 0.01% of outstanding | $240 | Dec 18, 2024 | none |
Transactions
Every row filed, 40 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 4, 2025 | Clare Fisher director | JOther Stock Option (Right to Buy)derivative | -38,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Shefali Agarwal director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Naiyer Rizvi director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | James Cho SVP, CHIEF ACCOUNTING OFFICER | JOther Common Stock | -155,123 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Stephen W Webster director | JOther Common Stock | -25,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Vassiliki Economides EVP, CHIEF FINANCIAL OFFICER | JOther Common Stock | -250,437 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Elaine Jones V director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Lawrence Corey director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Shefali Agarwal director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Clare Fisher director | JOther Stcok Option (right to buy)derivative | -8,693 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Vassiliki Economides EVP, CHIEF FINANCIAL OFFICER | JOther Stock Option (Right to Buy)derivative | -215,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Stephen W Webster director | JOther Stock Option (Right to Buy)derivative | -103,600 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Lawrence Corey director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Elaine Jones V director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | James Cho SVP, CHIEF ACCOUNTING OFFICER | JOther Stock Option (Right to Buy)derivative | -109,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Naiyer Rizvi director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Stephen W Webster director | JOther Stock Option (Right to Buy)derivative | -7,379 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Elaine Jones V director | JOther Stcok Option (right to buy)derivative | -19,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Naiyer Rizvi director | JOther Stock Option (Right to Buy)derivative | -19,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Clare Fisher director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Vassiliki Economides EVP, CHIEF FINANCIAL OFFICER | JOther Stock Option (Right to Buy)derivative | -215,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Lawrence Corey director | JOther Stcok Option (right to buy)derivative | -38,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | James Cho SVP, CHIEF ACCOUNTING OFFICER | JOther Stock Option (Right to Buy)derivative | -65,400 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Shefali Agarwal director | JOther Stock Option (Right to Buy)derivative | -38,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Clare Fisher director | JOther Stock Option (Right to Buy)derivative | -51,800 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | James Cho SVP, CHIEF ACCOUNTING OFFICER | JOther Stock Option (Right to Buy)derivative | -26,300 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Elaine Jones V director | JOther Stock Option (Right to Buy)derivative | -19,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Vassiliki Economides EVP, CHIEF FINANCIAL OFFICER | JOther Stock Option (Right to Buy)derivative | -138,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Shefali Agarwal director | JOther Stock Option (Right to Buy)derivative | -937 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Naiyer Rizvi director | JOther Stock Option (Right to Buy)derivative | -7,500 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | James Cho SVP, CHIEF ACCOUNTING OFFICER | JOther Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Elaine Jones V director | JOther Stock Option (Right to Buy)derivative | -12,500 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Shefali Agarwal director | JOther Stock Option (Right to Buy)derivative | -19,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Naiyer Rizvi director | JOther Stock Option (Right to Buy)derivative | -38,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Elaine Jones V director | JOther Stock Option (Right to Buy)derivative | -15,942 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Naiyer Rizvi director | JOther Stock Option (Right to Buy)derivative | -937 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | James Cho SVP, CHIEF ACCOUNTING OFFICER | JOther Stock Option (Right to Buy)derivative | -40,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Naiyer Rizvi director | JOther Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Apr 4, 2025 | Naiyer Rizvi director | JOther Stock Option (Right to Buy)derivative | -4,347 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Dec 18, 2024 | Vassiliki Economides EVP, CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock | -12,000 | $0.02 | $180 | 250,437 | Dec 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Shefali Agarwaldirector
- James ChoSVP, CHIEF ACCOUNTING OFFICER
- Lawrence Coreydirector
- Vassiliki EconomidesEVP, CHIEF FINANCIAL OFFICER
- Clare Fisherdirector
- Elaine Jones Vdirector
- Naiyer Rizvidirector
- Stephen W Websterdirector
Questions about GRTS
Answered from the filings on this page, as of the latest one.
Are insiders buying GRTS?
No. In the last 90 days no insider at Gritstone bio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade GRTS on the open market?
Vassiliki Economides (EVP, CHIEF FINANCIAL OFFICER) sold $180 of GRTS on Dec 18, 2024 and filed the Form 4 on Dec 20, 2024. InsiderTell scored 22 (weak).
How many insiders file Form 4 at Gritstone bio, Inc.?
8 people have filed a Form 4 at Gritstone bio, Inc., among them Shefali Agarwal (director), James Cho (SVP, CHIEF ACCOUNTING OFFICER), Lawrence Corey (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.